0.6 C
New York
Wednesday, February 1, 2023

Momentum Is Strong For TG Therapeutics Inc. (NASDAQ: TGTX)

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for TG Therapeutics Inc. (TGTX) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.07, or 0.59%, to $11.89. The TG Therapeutics Inc. has recorded 26,013 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed TG Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Stocks Info

This NASDAQ-listed company operates within the Biotechnology industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $11.82 and fluctuated between $12.25 as its day high and $11.69 as its day low. The current market capitalization of TG Therapeutics Inc. is $1.66B. A total of 2.79 million shares were traded on the day, compared to an average of 5.09M shares.

Insider trades can also provide insight into a stock’s future direction. During the recent three months, TGTX has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 6 BUYs and 0 SELLs from insiders. Insiders purchased 293,660 shares during that period but sold 0.

In the most recent transaction, Echelard Yann bought 9,000 shares of TGTX for 10.64 per share on Jan 06. After the transaction, the Director now owns 201,848 company shares. In a previous transaction on Jan 04, Charney Laurence N sold 30,000 shares at 11.10 per share. TGTX shares that Director owns now total 234,729.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for TGTX in the last 3 months, the mean price target is $20.56 with high estimates of $40.00 and low estimates of $6.00. In terms of 52-week highs and lows, TGTX has a high of $15.26 and a low of $3.48.

As of this writing, TGTX has an earnings estimate of -$0.34 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.19 per share and a lower estimate of -$0.47. The company reported an EPS of -$0.51 in the last quarter, which was 13.60% higher than expectations of -$0.59.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 9 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for TGTX is Overweight with a score of 4.22. A total of 7 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 1 thought it should be Sold.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles